

Clomiphene Citrate Informed Consent

What is Clomiphene Citrate?

Clomiphene Citrate is a medication given to increase production of the hormone FSH (Follicle Stimulating Hormone) in early part of the menstrual cycle. A high level of FSH production stimulates the follicles to grow. Because the key to Clomiphene Citrate therapy is to increase FSH production early in the cycle, you will usually take the medication in the beginning of your menstrual cycle (the start day will usually be day 3-5). There are many different ways in which Clomiphene is given, depending on the reason you are taking Clomiphene.

What are the risks of Clomiphene Therapy?

1. **Ovarian Hyperstimulation Syndrome:** This syndrome can be categorized into mild, moderate and severe forms. In the mild form, the ovaries are enlarged and abdominal pain and swelling develops. This is a self-limited process and generally does not require therapy. The moderate form of ovarian hyperstimulation syndrome results in extensive ovarian enlargement and the accumulation of a large amount of fluid in the abdomen. Nausea and vomiting may develop which may require medication for treatment, but hospitalization is usually not required. Severe hyperstimulation syndrome can be a life-threatening condition but is rarely seen with Clomiphene therapy.
2. **Multiple Births:** There is a risk with multiple pregnancies obtained with Clomiphene that have resulted in multiple births, with a majority of these being twins. The chance of higher multiples such as triplets and quadruplets exists but the percentage is very small.
3. Some epidemiological studies have suggested a possible association of fertility drugs and ovarian tumors, including ovarian cancer. Ovarian cancer is one of the least common forms of cancer that affect women overall. For example, over a lifetime, a woman's risk of developing ovarian cancer is 1.8%. Unfortunately, this rare disease may be more frequent in women with infertility and/or women who have never been pregnant. Several retrospective epidemiological studies have reported a possible association with ovarian cancer and fertility drugs. However, it is not known whether infertile women who have taken these medications are truly at a greater risk than infertile women who have not utilized these therapeutic interventions.

I hereby give permission to Beverly Hills Reproductive Fertility Center to prescribe the medication and to obtain blood and ultrasounds as indicated. My signature below indicates that I have been through the process of informed consent and have accepted of Clomiphene therapy and that all questions have been answered to my satisfaction.

Patient Name (Please Print)

Patient Signature

Date

Witness Signature

Date